Idiopathic short stature: Management and growth hormone treatment

Wit, J. M.; Reiter, Edward O.; Ross, Judith L.; Saenger, Paul; Savage, Martin O.; Rogol, Alan D.; Cohen, Pinchas

doi:10.1016/j.ghir.2007.11.003

Cited by 71 publications

(60 citation statements)

References 255 publications

(349 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Îáîâ'ÿçêîâîþ óìîâîþ äëÿ ä³àãíîñ-òèêè öüîãî ñòàíó º íîðìàëüíèé âì³ñò ãîðìîíó ðîñòó (ÃÐ) ó êðîâ³ õâîðîãî, çàäîâ³ëüíèé âèêèä ÃÐ íà òë³ ñòèìóëÿö³éíèõ òåñò³â, íîðìàëüí³ äîâ-aeèíà òà ìàñà ò³ëà íà ÷àñ íàðîäaeåííÿ. Çà îö³í-êàìè áàãàòüîõ äîñë³äíèê³â, ñòàí 60-80% óñ³õ ä³-òåé, ÿê³ ìàþòü â³äñòàâàííÿ ó çðîñò³ äî ì³íóñ 2 SD, ï³äõîäèòü ï³ä âèçíà÷åííÿ ²Í [1][2][3][4] .…”

Section: ідіопатична низькорослість: клініко-діагностичні критеріїunclassified

“…Çàñòîñóâàííÿ îö³íêè ê³ñòêîâîãî â³êó (ÊÂ) ÿê ä³àãíîñòè÷íîãî êðèòåð³þ êîíñòèòóö³éíî¿ çàòðèìêè ðîñòó íå çàâaeäè º ïðàâèëüíèì ÷åðåç òå, ùî çàòðèìêà ÊÂ íå çàâaeäè â³äïîâ³äàº òåð-ì³íàì çàòðèìêè ïóáåðòàòó. Äåÿê³ ä³òè ³ç çàòðèì-êîþ ê³ñòêîâîãî â³êó â÷àñíî âñòóïàþòü ó ïóáåð-òàò [3][4][5].…”

Section: ідіопатична низькорослість: клініко-діагностичні критеріїunclassified

“…Êàð³îòèï ìàº áóòè âèçíà÷åíèì â óñ³õ ä³â÷èíîê ³ç íåç'ÿñîâàíîþ ïðè÷èíîþ çàòðèìêè ðîñòó òà ó õëîï÷èê³â ç³ ñòàòåâèìè â³äõèëåííÿìè. Òàêîae âñòàíîâëþºòüñÿ ÊÂ çà ðåíòãåíîãðàìîþ ê³ñòîê ðóê [1][2][3][4].…”

Section: ідіопатична низькорослість: клініко-діагностичні критеріїunclassified

See 2 more Smart Citations

Idiopathic short stature: Clinical-diagnostic criteria

Bolshova¹,

Самсон²,

Спринчук³

et al. 2013

CE&ES

View full text Add to dashboard Cite

Section: ідіопатична низькорослість: клініко-діагностичні критеріїunclassified

See 1 more Smart Citation

Idiopathic short stature: Clinical-diagnostic criteria

Bolshova¹,

Самсон²,

Спринчук³

et al. 2013

CE&ES

View full text Add to dashboard Cite

“…There are essentially four outcome parameters of GH treatment that can be considered: short-term growth response (first year's height velocity), bone age (BA) advance, onset and progress of puberty, and increase in adult height (AH). As recently reviewed (1,2), almost all children with ISS respond to GH treatment with an increase in height velocity, even at a relatively low dose. The dose-response curve for the first year's height velocity appears to reach a plateau after a dose of 50 mg/kg per day.…”

Section: Introductionmentioning

confidence: 97%

“…The dose-response curve for the first year's height velocity appears to reach a plateau after a dose of 50 mg/kg per day. No acceleration of BA advance and pubertal onset and progress has been observed in the dose range of 30-53 mg/kg per day, and the most effective dose regimen (50 mg/kg per day) leads to w7 cm AH gain (1,2).…”

Section: Introductionmentioning

confidence: 98%

High-dose GH treatment limited to the prepubertal period in young children with idiopathic short stature does not increase adult height

Gool

Kamp

Odink

et al. 2010

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: To assess the long-term effect of prepubertal high-dose GH treatment on growth in children with idiopathic short stature (ISS). Design and methods: Forty children with no signs of puberty, age at start 4-8 years (girls) or 4-10 years (boys), height SDS !K2.0 SDS, and birth length OK2.0 SDS, were randomly allocated to receive GH at a dose of 2 mg/m 2 per day (equivalent to 75 mg/kg per day at start and 64 mg/kg per day at stop) until the onset of puberty for at least 2 years (preceded by two 3-month periods of treatment with low or intermediate doses of GH separated by two washout periods of 3 months) or no treatment. In 28 cases, adult height (AH) was assessed at a mean (S.D.) age of 20.4 (2.3) years. Results: GH-treated children (mean treatment period on high-dose GH 2.3 years (range 1.2-5.0 years)) showed an increased mean height SDS at discontinuation of the treatment compared with the controls (K1.3 (0.8) SDS versus K2.6 (0.8) SDS respectively). However, bone maturation was significantly accelerated in the GH-treated group compared with the controls (1.6 (0.4) versus 1.0 (0.2) years per year, respectively), and pubertal onset tended to advance. After an untreated interval of 3-12 years, AH was K2.1 (0.7) and K1.9 (0.6) in the GH-treated and control groups respectively. Age was a positive predictor of adult height gain. Conclusion: High-dose GH treatment restricted to the prepubertal period in young ISS children augments height gain during treatment, but accelerates bone maturation, resulting in a similar adult height compared with the untreated controls.

show abstract

Children's psychosocial functioning and parents' quality of life in paediatric short stature: The mediating role of caregiving stress

Silva

Bullinger

Sommer

et al. 2017

Clin Psychology and Psychoth

View full text Add to dashboard Cite

better QoL, via less caregiving stress, and these links were invariant across diagnoses, treatment status and current height deviation. Conclusions. These results suggest that, along with GH treatments, multidisciplinary interventions in pediatric endocrinology should be family-centered, by targeting both the children's psychosocial functioning and the parents' stress, in order to improve individual and family adaptation.

show abstract

Idiopathic short stature: Management and growth hormone treatment

Cited by 71 publications

References 255 publications

Idiopathic short stature: Clinical-diagnostic criteria

Idiopathic short stature: Clinical-diagnostic criteria

High-dose GH treatment limited to the prepubertal period in young children with idiopathic short stature does not increase adult height

Children's psychosocial functioning and parents' quality of life in paediatric short stature: The mediating role of caregiving stress

Contact Info

Product

Resources

About